Overview

Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies

Status:
Terminated
Trial end date:
2017-08-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or relapsed from prior interferon-based therapies (pegylated or standard) either alone or in combination with ribavirin or other anti-HCV therapies including direct-acting anti-viral agents.
Phase:
Phase 2
Details
Lead Sponsor:
TaiwanJ Pharmaceuticals Co., Ltd